甲状腺激素与非酒精性脂肪性肝病研究进展

Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease

非酒精性脂肪性肝病(NAFLD)是肝硬化、肝癌和肝移植的重要原因.全球成年人患病率约为25%,且呈现上升趋势.大量的研究表明甲状腺激素(TH)在肝脏脂质代谢和胰岛素抵抗过程中起着重要的作用,甲状腺激素受体激动剂有望成为治疗NAFLD的新型药物.本文就甲状腺激素与NAFLD的研究进展进行了综述.

The nonalcoholic fatty liver disease(NAFLD)is considered to be the metabolic disorders in liver and is closely related to obesity,insulin resistance(IR),type 2 diabetes mellitus(T2DM)and hyperlipemia,etc.The prevalence of NAFLD among adults worldwide is about 25%and it is to believe increasing year by year.The NAFLD is an important causes of liver cirrhosis,liver cancer and liver transplantation.A large number of studies have shown that thyroid hormone(THs)plays an important role in hepatic lipid metabolism and IR,and the thyroid hormone receptor agonists are expected to become new medicines for the treatment of patients with NAFLD.In this review,we mainly discuss the progress of THs in patients with NAFLD.